MaaT Pharma Logo

MaaT Pharma

A clinical-stage biotech developing microbiome-based therapeutics for oncology.

MAAT | PA

Overview

Corporate Details

ISIN(s):
FR0012634822 (+1 more)
LEI:
969500CQQB6XUNW6CN97
Country:
France
Address:
70 AVENUE TONY GARNIER, 69007 LYON

Description

MaaT Pharma is a clinical-stage biotechnology company specializing in the development of microbiome-based therapeutics. The company's primary focus is on oncology, aiming to improve survival outcomes for cancer patients by modulating the immune system through the gut microbiome. It develops Microbiome Ecosystem Therapies (MET) designed to restore gut microbiome symbiosis. The company's pipeline includes product candidates for treating complications in patients with blood cancers and solid tumors, with its lead candidate, MaaT013, in late-stage development for acute Graft-versus-Host Disease (aGvHD). MaaT Pharma utilizes an AI-powered platform for drug development and has its own cGMP manufacturing capabilities.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-13 19:40
Inside Information / Other news releases
English 193.4 KB
2025-11-13 19:40
Informations privilégiées / Autres communiqués
French 156.5 KB
2025-11-05 07:30
Inside Information / Other news releases
English 162.7 KB
2025-11-05 07:30
Informations privilégiées / Autres communiqués
French 132.6 KB
2025-11-04 07:30
Inside Information / News release on accounts, results
English 109.1 KB
2025-11-04 07:30
Informations privilégiées / Communiqué sur comptes, résultats
French 167.6 KB
2025-10-07 07:30
Informations privilégiées / Autres communiqués
French 930.2 KB
2025-09-17 07:30
Inside Information / Information on annual revenues
English 190.8 KB
2025-09-17 07:30
Informations privilégiées / Information sur chiffre d’affaires annuel
French 204.2 KB
2025-07-28 07:30
Informations privilégiées / Autres communiqués
French 158.6 KB
2025-07-28 07:30
Inside Information / Other news releases
English 106.4 KB
2025-06-13 07:30
Informations privilégiées / Autres communiqués
French 127.5 KB
2025-06-13 07:30
Inside Information / Other news releases
English 151.0 KB
2025-06-02 18:30
Inside Information / Other news releases
English 135.6 KB
2025-06-02 18:30
Informations privilégiées / Autres communiqués
French 166.2 KB

Automate Your Workflow. Get a real-time feed of all MaaT Pharma filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for MaaT Pharma

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for MaaT Pharma via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2024-07-12 N/A Other Sell 8 60.87 EUR
2024-07-11 N/A Other Sell 57 436.14 EUR
2023-12-22 N/A Other Buy 2,940 14,994.00 EUR
2023-12-22 N/A Other Buy 1,960 9,996.00 EUR
2023-09-27 N/A Other Buy 500 3,050.00 EUR

Peer Companies

Isofol Medical Logo
Clinical-stage biotech developing a folate-based therapy to enhance cancer treatments.
Sweden
ISOFOL
IVIM Technology, Inc. Logo
Provides intravital microscopy systems and CRO services for biomedical research.
South Korea
460470
IXICO PLC Logo
Provides AI-driven neuroimaging and data analytics for neuroscience clinical trials.
United Kingdom
IXI
Jade Biosciences, Inc. Logo
A clinical-stage biotech developing therapies for autoimmune and inflammatory diseases.
United States of America
JBIO
Jasper Therapeutics, Inc. Logo
A clinical-stage biotech developing therapies targeting mast and hematopoietic stem cells.
United States of America
JSPR
J. Molner AS Logo
A CDRO developing generic sterile injectable and dermatological dosage forms.
Estonia
JML
Kadimastem Ltd. Logo
Clinical-stage cell therapy company developing treatments for ALS and diabetes.
Israel
KDST
KAINOS MEDICINE, INC. Logo
Develops small molecule therapeutics for neurodegenerative, infectious, and oncological diseases.
South Korea
284620
Kairos Pharma, LTD. Logo
Develops oncology therapies targeting drug resistance and immune suppression.
United States of America
KAPA
Kancera Logo
Pharmaceutical company seeking a reverse takeover to leverage its public listing.
Sweden
KAN

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.